Longgang Cui

545 total citations · 1 hit paper
17 papers, 383 citations indexed

About

Longgang Cui is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Longgang Cui has authored 17 papers receiving a total of 383 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Longgang Cui's work include Cancer Immunotherapy and Biomarkers (9 papers), Cancer Genomics and Diagnostics (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Longgang Cui is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Cancer Genomics and Diagnostics (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Longgang Cui collaborates with scholars based in China, United States and Spain. Longgang Cui's co-authors include Yuezong Bai, Xiaochen Zhao, Shangli Cai, Zhengyi Zhao, Yuzi Zhang, Guoqiang Wang, Jianchun Duan, Depei Huang, Mengli Huang and Jia Song and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Cancer and Frontiers in Oncology.

In The Last Decade

Longgang Cui

15 papers receiving 380 citations

Hit Papers

Use of Immunotherapy With Programmed Cell Death 1 vs Prog... 2019 2026 2021 2023 2019 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
    2019 249 citations Jianchun Duan, Longgang Cui et al. JAMA Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Longgang Cui China 7 297 159 72 65 61 17 383
Ignazio Martellucci Italy 11 280 0.9× 110 0.7× 73 1.0× 67 1.0× 64 1.0× 16 356
Alessandro Dal Maso Italy 10 286 1.0× 200 1.3× 99 1.4× 48 0.7× 71 1.2× 25 388
Giulia Grizzi Italy 12 262 0.9× 185 1.2× 70 1.0× 30 0.5× 82 1.3× 24 370
Nishi Kothari United States 12 238 0.8× 155 1.0× 74 1.0× 39 0.6× 93 1.5× 29 372
Ilze Bāra United States 9 260 0.9× 225 1.4× 38 0.5× 40 0.6× 57 0.9× 22 365
Wenxiao Jia China 10 219 0.7× 157 1.0× 88 1.2× 57 0.9× 95 1.6× 25 374
Virginia Palomar Coloma France 4 421 1.4× 190 1.2× 48 0.7× 118 1.8× 42 0.7× 5 481
Éléonore De Guillebon France 9 335 1.1× 116 0.7× 62 0.9× 184 2.8× 98 1.6× 13 462
Rachel Anhorn United States 5 211 0.7× 125 0.8× 127 1.8× 66 1.0× 65 1.1× 7 329
Byung Woog Kang South Korea 10 241 0.8× 193 1.2× 44 0.6× 88 1.4× 66 1.1× 21 406

Countries citing papers authored by Longgang Cui

Since Specialization
Citations

This map shows the geographic impact of Longgang Cui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Longgang Cui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Longgang Cui more than expected).

Fields of papers citing papers by Longgang Cui

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Longgang Cui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Longgang Cui. The network helps show where Longgang Cui may publish in the future.

Co-authorship network of co-authors of Longgang Cui

This figure shows the co-authorship network connecting the top 25 collaborators of Longgang Cui. A scholar is included among the top collaborators of Longgang Cui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Longgang Cui. Longgang Cui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Yue, Dongsheng, Weiran Liu, Chen Chen, et al.. (2022). Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients. Translational Lung Cancer Research. 11(2). 263–276. 63 indexed citations
2.
Gao, Guanghui, Longgang Cui, Fei Zhou, et al.. (2022). Special issue “The advance of solid tumor research in China”: FGFR4 alterations predict efficacy of immune checkpoint inhibitors in nonsmall cell lung cancer. International Journal of Cancer. 152(1). 79–89. 3 indexed citations
3.
Wang, Zhenghang, Chang Liu, Yuezong Bai, et al.. (2021). Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer. Frontiers in Oncology. 11. 761110–761110. 8 indexed citations
4.
Shen, Dong, Junling Zhang, Kai Yuan, et al.. (2021). Landscape of IDH1/2 mutations in Chinese patients with solid tumors: A pan‐cancer analysis. Molecular Genetics & Genomic Medicine. 9(8). e1697–e1697. 9 indexed citations
5.
Hu, Yi, Longgang Cui, Xiaochen Zhao, Yuezong Bai, & Fan Zhang. (2021). Investigation of immune microenvironment in EGFR mutant NSCLC.. Journal of Clinical Oncology. 39(15_suppl). e20517–e20517. 1 indexed citations
6.
Hu, Yi, Xiaochen Zhao, Yuezong Bai, Longgang Cui, & Fan Zhang. (2021). Comparing active immunotherapy efficacy of PD-L1 ≥ 50% NSCLC patients: A systematic review and meta-analysis.. Journal of Clinical Oncology. 39(15_suppl). e21139–e21139.
7.
Cui, Longgang, et al.. (2021). Comparing of pan-cancer tumor immune microenvironment.. Journal of Clinical Oncology. 39(15_suppl). e15100–e15100.
8.
Zhou, Jing, Zhengyi Zhao, Longgang Cui, et al.. (2020). Pathogenic Germline Mutations in Chinese Patients with Gastric Cancer Identified by Next-Generation Sequencing. Oncology. 98(8). 583–588. 8 indexed citations
9.
Zhang, Fan, Di Huang, Lei Zhao, et al.. (2020). Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy. Therapeutic Advances in Medical Oncology. 12. 3863551922–3863551922. 20 indexed citations
10.
Yin, Yongmei, Wei Zuo, Zhengyi Zhao, et al.. (2020). Genomic landscape of FGF/FGFR pathway alternations across 12,372 pan-cancer patients.. Journal of Clinical Oncology. 38(15_suppl). e13503–e13503. 1 indexed citations
11.
Wu, Hao, Jing Zhao, Zhengyi Zhao, et al.. (2020). Landscape of RAS variations in 17993 solid tumors: A pan-cancer analysis.. Journal of Clinical Oncology. 38(15_suppl). e15615–e15615. 1 indexed citations
12.
Duan, Jianchun, Longgang Cui, Xiaochen Zhao, et al.. (2019). Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer. JAMA Oncology. 6(3). 375–375. 249 indexed citations breakdown →
13.
Li, Tao, Fan Zhang, Zhaozhen Wu, et al.. (2019). PLEKHM2-ALK: A novel fusion in small-cell lung cancer and durable response to ALK inhibitors. Lung Cancer. 139. 146–150. 14 indexed citations
14.
15.
Duan, Jianchun, Longgang Cui, Guoqiang Wang, et al.. (2019). Immunotherapy efficacy and safety of programmed cell death 1 (PD-1) versus programmed death ligand-1 (PD-L1) inhibitors in pan-cancer: A systematic review and meta-analysis.. Journal of Clinical Oncology. 37(15_suppl). e14113–e14113. 1 indexed citations
16.
Duan, Jianchun, Longgang Cui, Zhengyi Zhao, et al.. (2019). Immunotherapy efficacy and patients' age: A systematic review and meta-analysis.. Journal of Clinical Oncology. 37(15_suppl). e14168–e14168. 1 indexed citations
17.
Yang, Weili, et al.. (2017). [Consensus on pathologic diagnosis of Wilms' tumor in children].. PubMed. 46(3). 149–154. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ignazio Martellucci Breakdown of academic impact, for papers by Alessandro Dal Maso Breakdown of academic impact, for papers by Giulia Grizzi Breakdown of academic impact, for papers by Nishi Kothari Breakdown of academic impact, for papers by Ilze Bāra Breakdown of academic impact, for papers by Wenxiao Jia Breakdown of academic impact, for papers by Virginia Palomar Coloma Breakdown of academic impact, for papers by Éléonore De Guillebon Breakdown of academic impact, for papers by Rachel Anhorn Breakdown of academic impact, for papers by Byung Woog Kang
Rankless by CCL
2026